Skip to search formSkip to main contentSkip to account menu

monoclonal antibody CNTO 328

Known as: CNTO-328, monoclonal antibody CNTO-328, CNTO 328 monoclonal antibody 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

siltuximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Gateways to clinical trials.
(+)-Dapoxetine hydrochloride, [(123)I]-BZA, 9-Aminocamptothecin; Abacavir sulfate/lamivudine, Adalimumab, Adefovir dipivoxil… 
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Alemtuzumab, Amlodipine, Anakinra, Azacitidine; Bazedoxifene acetate, Belinostat, Bevacizumab, BI-201335, BI-2536… 
2008
2008
A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.
Interleukin (IL)-6 is a multifunctional cytokine that serves as a growth factor for B-cell non-Hodgkin’s lymphoma (NHL), multiple… 
2008
2008
Gateways to clinical trials.
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC… 
2006
2006
Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328
Interleukin‐6 (IL‐6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP‐IL‐6+ cells selected in the… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… 
2006
2006
Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies.
2513 Background: IL-6 is implicated in the pathophysiology of several malignant diseases, including multiple myeloma (MM) and… 
2006
2006
CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.
Background: IL-6 is a pleiotropic cytokine, the dysregulation of which plays an etiological role in many diseases. Multicentric… 
2004
2004
Interterleukin-6 (IL-6) Produced by Monocyte Activation Reduces Dendritic Cell (DC) Differentiation in Patients with Multiple Myeloma (MM) and Malignant Lymphoma (ML): Role of CNTO 328, an Anti-IL-6…
We developed a serum-free process in a closed system using culture cassettes and bags for large-scale and clinical-grade DC… 
2004
2004
Correlation of serum CNTO 328-Anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients.
2560 Background: RCC is the most common malignant tumor of the kidney and is associated with high expression of interleukin-6 (IL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)